Join HHMI investigators in a public dialogue about stem cells and their evolving role in treating disease.
If one could harness the power of stem cells, one might be able to treat multigenic diseases like Type I diabetes, osteoporosis, Alzheimer's and Parkinson's that now affect more than 128 million people, according to Dr. Douglas Melton, a Howard Hughes Medical Institute (HHMI) Investigator at Harvard University.
Join us for an April 24 public dialogue with Dr. Melton who will describe his efforts to teach stem cells how to differentiate into pancreatic beta cells, the very cells that fail in type 1 or juvenile diabetes. This is the second in the seminar series on biotechnology and public policy presented by HHMI and the Center for Strategic and International Studies for the Washington policy community.
Dr. Melton will be joined by Dr. Gerald Shulman, HHMI Investigator and Professor of Endocrinology and Cellular and Molecular Physiology at the Yale School of Medicine, whose research on insulin resistance and the factors that may predispose individuals to developing adult-onset diabetes—even when they lack obvious risk factors for the disease—may lead to medical breakthroughs to help mitigate this devastating affliction.
Dr. James R. Gavin, President of the Morehouse School of Medicine, will open the session by describing the public health dimensions of diabetes that in the United States affects 6 percent of the population over age 18 and 15 percent of the population over 65. Diabetes is the leading cause of blindness and non-traumatic loss of limb, and accounts for 25 percent of all new cases of end-stage renal failure.
The session will take place on April 24, 2003 from 12 p.m. to 2 p.m. in the Senate Dirksen Building, SDG-11. Lunch will be provided. Please RSVP by E-mail to email@example.com with your full contact information. Questions can be directed to Sophia Siddiqui, at (202) 775-3244.